About
Headquartered in Delanson, NY, Resolys Bio, Inc., a Delaware Corporation, (“Resolys” or the “Company”) is a privately held pharmaceutical Company formed in 2016 by Beech Tree Labs, Inc. (“Beech Tree Labs”) to commercialize two pharmaceutical products that it developed– oxidized streptolysin O (“oSLO”) and a proprietary multi-component compound (“MCC”). These products utilize cellular signaling to impact several medical conditions. oSLO modulates, and in some cases reverses, the symptoms associated with chronic traumatic brain injury (“cTBI”). MCC can ameliorate pain and fatigue of patients with a form of joint hypermobility called hypermobile Ehlers Danlos Syndrome (“hEDS”) The Company’s leadership includes a number of current and former biotech CEOs and embodies over 150 years of combined experience in building successful enterprises.
DelansonBiotechnology